Drugs / VDPHL01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06527365 | Jul 2024 → Aug 2026 overdue | baldness, male pattern | Veradermics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT06724614 | Nov 2024 → Feb 2026 overdue | baldness, male pattern | Veradermics, Inc. | Active not recruiting | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07146022 | Jul 2025 → Jun 2027 expected | androgenetic alopecia | Veradermics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06972264 | Mar 2025 → Dec 2026 expected | baldness, male pattern | Veradermics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-17 | Veradermics, Inc. | Results Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy veradermics.com ↗
The new data include results from an age-based subgroup analysis of the efficacy and safety of VDPHL01 in males less than 40 years of age (<40) and males 40 years of age and older (≥40). |
| 2026-07-15 | Veradermics, Inc. | Results Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout veradermics.com ↗ |
| 2026-04-27 | Veradermics, Inc. | Results Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss veradermics.com ↗
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial (Study ‘302’) evaluating VDPHL01 |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VDPHL01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07146022 ↗ |
| Route | Oral | “investigational oral drug” NCT06527365 ↗ |